CA3040264C - Systemes replicons de virus recombinants et leurs utilisations - Google Patents

Systemes replicons de virus recombinants et leurs utilisations

Info

Publication number
CA3040264C
CA3040264C CA3040264A CA3040264A CA3040264C CA 3040264 C CA3040264 C CA 3040264C CA 3040264 A CA3040264 A CA 3040264A CA 3040264 A CA3040264 A CA 3040264A CA 3040264 C CA3040264 C CA 3040264C
Authority
CA
Canada
Prior art keywords
nucleic acid
modified
replicon rna
utr
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3040264A
Other languages
English (en)
Other versions
CA3040264A1 (fr
Inventor
Kurt Iver Kamrud
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Priority claimed from PCT/US2017/054928 external-priority patent/WO2018075235A1/fr
Publication of CA3040264A1 publication Critical patent/CA3040264A1/fr
Application granted granted Critical
Publication of CA3040264C publication Critical patent/CA3040264C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne d'une manière générale des systèmes d'expression à base de virus convenant à la production de molécules d'intérêt. La présente invention concerne des constructions d'acides nucléiques, telles que des vecteurs d'expression, contenant un ARN réplicon modifié qui comprend une région non traduite (5') modifiée (5'-UTR) et, éventuellement, au moins une partie de sa séquence virale d'origine codant pour des protéines structurelles ayant été supprimée. L'invention concerne également des procédés de production de polypeptides d'intérêt.
CA3040264A 2016-10-17 2017-10-03 Systemes replicons de virus recombinants et leurs utilisations Active CA3040264C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409228P 2016-10-17 2016-10-17
US62/409,228 2016-10-17
PCT/US2017/054928 WO2018075235A1 (fr) 2016-10-17 2017-10-03 Systèmes réplicons de virus recombinants et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3040264A1 CA3040264A1 (fr) 2018-04-26
CA3040264C true CA3040264C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US20230126773A1 (en) Recombinant virus replicon systems and uses thereof
US20240209379A1 (en) Compositions and methods for enhancing gene expression
AU699384B2 (en) Alphavirus cDNA vectors
JP5727420B2 (ja) アルファウイルス粒子及び調製方法
Kim et al. Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution
JP3786956B2 (ja) アルファウイルス発現ベクター
EP1141361B1 (fr) Compositions et methodes permettant l'encapsidation de vecteurs d'alphavirus
JPH11505719A (ja) アルファウイルスｒｎａレプリコン系
Volkova et al. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells
CA3040264C (fr) Systemes replicons de virus recombinants et leurs utilisations
Schlesinger Alphavirus expression vectors
JP5284086B2 (ja) サケ科魚類のアルファウイルスのｃＤＮＡ構築物
US20080096274A1 (en) Recombinant alphavirus vectors and methods of using same
WO2024133550A1 (fr) Système d'auto-amplification eucaryote